Clinical trials: gemcitabine hydrochloride
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
- Trial name
- NCT02049905
- Testing
- Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 433 people
- Sponsor
- ImmunityBio, Inc.
Metastatic Breast Cancer
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages.
- Trial name
- Morpheus-panBC (NCT03424005)
- Testing
- Capecitabine, Atezolizumab, Ipatasertib
- Where
- 55 sites in United States, Australia and 7 more
- Volunteers
- 1,132 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Ductal Adenocarcinoma (PDAC)
ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel…
- Trial name
- NCT06182072
- Testing
- ProAgio Dose Levels (DL) 1,2,3,4, Gemcitabine, nab paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- ProDa BioTech, LLC
Liver Metastases, Recurrent Colon Cancer
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
- Trial name
- NCT00645710
- Testing
- gemcitabine hydrochloride, floxuridine, proteomic profiling
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Treatment, Peripheral T-cell Lymphoma
Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL
This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy mitoxantrone hydrochloride liposome in combination with gemcitabine, dexamethasone, and cisplatin in…
- Trial name
- NCT05441761
- Testing
- liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
- Where
- 5 sites in China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cancer
Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
The 5 year survival of patients with locally advanced or metastatic pancreatic cancer is less than 5 %. Since the introduction of gemcitabine, further advances in therapy in the advanced/metastatic setting have been extremely…
- Trial name
- MATRIX (NCT02358161)
- Testing
- gemcitabine and nab paclitaxel
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Advanced Cancers, Lymphoma
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab.
- Trial name
- NCT01983969
- Testing
- Azacitidine, Vorinostat, Gemcitabine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Carcinoma NSCLC
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal…
- Trial name
- NCT03003962
- Testing
- Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin
- Where
- 92 sites in United States, Australia and 10 more
- Volunteers
- 669 people
- Sponsor
- AstraZeneca
Biliary Tract Cancer, PD-1 Antibody
Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
The aim of this study is to assess the R0 resection rate of tislelizumab combined with Lenvatinib and Gemox chemotherapy in the conversion therapy of potentially resectable locally advanced BTC.
- Conditions
- Biliary Tract Cancer, PD-1 Antibody, Gemox, Lenvatinib
- Trial name
- NCT05156788
- Testing
- PD-1+Lenvatinib+GEMOX
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and effective as 3rd line treatment for patients with…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer
- Trial name
- NCT01510561
- Testing
- 90Y-hPAM4, 90Y-hPAM4 + gemcitabine
- Where
- 24 sites in United States
- Sponsor
- Gilead Sciences
Colorectal Cancer
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276861
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Miami
Local Tumor Spread, Advanced Cancer
Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer
To compare the quality of life (QoL) in patients receiving a bilioenteric anastomosis vs. endoscopical stenting for palliation of biliary obstruction due to locally unresectable or metastatic pancreatic cancer.
- Conditions
- Local Tumor Spread, Advanced Cancer, Metastasized, Pancreatic Cancer Non-resectable
- Trial name
- BYPAPA (NCT01887041)
- Testing
- Stent, Biliodigestive anastomosis
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Triple Negative Breast Neoplasms
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC).
- Trial name
- NCT06841354
- Testing
- Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication
- Where
- 283 sites in United States, Argentina and 33 more
- Volunteers
- 1,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Soft Tissue Sarcoma
Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma
The purpose of this exploratory phase II study is to assess the effectiveness and safety profile of Endostar®(Recombinant Human Endostatin Injection) plus Gemcitabine and Docetaxel in treatment of soft tissue sarcoma patients…
- Trial name
- NCT01812018
- Testing
- Endostar, Gemcitabine, Docetaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peng Yuan
Intrahepatic Cholangiocarcinoma
TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma
This study is a prospective, multicenter, open, real-world clinical study. All eligible patients were assigned to experimental group (TACE combined with multi-target drugs and PD-1 inhibitors), and control group (conventional…
- Trial name
- NCT05247996
- Testing
- Transcatheter arterial chemoembolization, Multi-target Drug Therapy, Immunocheckpoint Inhibitor Therapy
- Volunteers
- 98 people
- Sponsor
- The Central Hospital of Lishui City
Liver Metastasis
Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor
The purpose of this study is to see if treatment with intrahepatic chemotherapy is a good options in patients with liver metastases.
- Trial name
- NCT01511146
- Testing
- Oxaliplatin, Mitomycin + Gemcitabine
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Copenhagen University Hospital at Herlev
Sarcoma
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227669
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 32 sites in France
- Volunteers
- 90 people
- Sponsor
- UNICANCER
Advanced Solid Tumour
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.
- Trial name
- NCT07111546
- Testing
- LBL-024 for Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection
- Where
- 16 sites in China
- Volunteers
- 140 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Pancreatic Cancer
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR6390 in combination with nab-paclitaxel and gemcitabine in first-line treatment of subjects with advanced/metastatic pancreatic cancer.
- Trial name
- NCT05185869
- Testing
- SHR6390, Nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Ruijin Hospital
HER2-negative Breast Cancer
Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer
This study intends to conduct a single-arm, open-label Phase II multicenter clinical study of gemcitabine combined with eribulin regimen in the treatment of second-line above recurrent HER2-negative breast cancer.
- Trial name
- NCT05263882
- Testing
- Gemcitabine combined with eribulin
- Volunteers
- 58 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.